ORGANOGENESIS HOLDINGS INC. Repayments of Secured Debt
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Repayments of Secured Debt of $66.56 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSecuredDebt · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. repayments of secured debt for the quarter ending 2024-12-31 was $62.34M, a 4330.99% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. repayments of secured debt for the quarter ending 2024-09-30 was $1.41M, a 0.00% change year-over-year.
- ORGANOGENESIS HOLDINGS INC. repayments of secured debt for the quarter ending 2024-06-30 was $1.41M, a 50.16% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. repayments of secured debt for the quarter ending 2024-03-31 was $1.41M, a 49.89% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. repayments of secured debt for fiscal 2024 was $66.56M, a 1319.86% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. repayments of secured debt for fiscal 2023 was $4.69M, a 66.65% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. repayments of secured debt for fiscal 2022 was $2.81M, a 199.89% increase from fiscal 2021.
- ORGANOGENESIS HOLDINGS INC. repayments of secured debt for fiscal 2021 was $938.00K.
| Period end | Repayments of Secured Debt 3 month | Repayments of Secured Debt 6 month | Repayments of Secured Debt 9 month | Repayments of Secured Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $62.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $63.75M derived: sum of 2 quarters · filed 2026-02-26 | $65.16M derived: sum of 3 quarters · filed 2026-02-26 | $66.56M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.81M derived: sum of 2 quarters · filed 2025-11-06 | $4.22M 10-Q · filed 2025-11-06 | $5.63M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.81M 10-Q · filed 2025-08-07 | $4.22M derived: sum of 3 quarters · filed 2026-02-26 | $5.63M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.41M 10-Q · filed 2025-05-08 | $2.81M derived: sum of 2 quarters · filed 2026-02-26 | $4.22M derived: sum of 3 quarters · filed 2026-02-26 | $5.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.81M derived: sum of 2 quarters · filed 2026-02-26 | $3.75M derived: sum of 3 quarters · filed 2026-02-26 | $4.69M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.34M derived: sum of 2 quarters · filed 2024-11-12 | $3.28M 10-Q · filed 2024-11-12 | $5.16M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $937.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.88M 10-Q · filed 2024-08-08 | $3.75M derived: sum of 3 quarters · filed 2025-02-27 | $3.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $938.00K 10-Q · filed 2024-05-09 | $2.81M derived: sum of 2 quarters · filed 2025-02-27 | $2.81M derived: sum of 3 quarters · filed 2025-02-27 | $3.28M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.88M derived: sum of 2 quarters · filed 2025-02-27 | $2.34M derived: sum of 3 quarters · filed 2025-02-27 | $2.81M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $469.00K derived: sum of 2 quarters · filed 2023-11-09 | $938.00K 10-Q · filed 2023-11-09 | $1.41M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $469.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $938.00K 10-Q · filed 2023-08-09 | $1.41M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2022-03-31 | $469.00K 10-Q · filed 2023-05-10 | $938.00K derived: sum of 2 quarters · filed 2024-02-29 | ||
| 2021-12-31 | $469.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $938.00K 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $469.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |